We are live on ! Find out more
REPL icon

Replimune Group

102 hedge funds and large institutions have $696M invested in Replimune Group in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 34 increasing their positions, 40 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

5% more capital invested

Capital invested by funds: $665M → $696M (+$31.4M)

1.35% less ownership

Funds ownership: 82.86%81.52% (-1.3%)

5% less funds holding

Funds holding: 107102 (-5)

15% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 40

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
102
Holders Change
-5
Holders Change %
-4.67%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
7
Increased
34
Reduced
40
Closed
11
Calls
$2.33M
Puts
Net Calls
+$2.33M
Net Calls Change
+$2.11M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$103M -$2.3M -140,229 -2%
OFM
2
Omega Fund Management
Massachusetts
$81.7M
RG
3
Redmile Group
California
$63.7M -$756K -46,003 -1%
BBA
4
Baker Bros. Advisors
New York
$62.8M +$32.5M +1,979,378 +123%
AVLSA
5
Atlas Venture Life Science Advisors
Massachusetts
$56.1M
BlackRock
6
BlackRock
New York
$40.6M +$3.09M +188,286 +9%
Vanguard Group
7
Vanguard Group
Pennsylvania
$30.7M +$2.18M +132,791 +8%
State Street
8
State Street
Massachusetts
$28.9M -$990K -60,283 -4%
EA
9
Emerald Advisers
Pennsylvania
$19.1M -$668K -40,689 -4%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$19.1M +$154K +9,380 +0.9%
EMFAT
11
Emerald Mutual Fund Advisers Trust
Pennsylvania
$17.2M
BI
12
BVF Inc
California
$16.2M
AG
13
Artal Group
Luxembourg
$15.7M
FLSM
14
Frazier Life Sciences Management
California
$14.1M +$1.47M +89,505 +12%
Morgan Stanley
15
Morgan Stanley
New York
$10.6M +$312K +18,972 +3%
Citadel Advisors
16
Citadel Advisors
Florida
$10.2M +$4.03M +245,262 +73%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$9.45M -$26K -1,583 -0.3%
CS
18
Candriam SCA
Luxembourg
$8.61M
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$8.27M +$2.11M +128,659 +37%
Amundi
20
Amundi
France
$7.57M +$941K +57,259 +18%
Schroder Investment Management Group
21
Schroder Investment Management Group
United Kingdom
$5.87M +$1.25M +75,812 +29%
Northern Trust
22
Northern Trust
Illinois
$5.48M +$195K +11,872 +4%
Goldman Sachs
23
Goldman Sachs
New York
$3.94M +$1.38M +84,123 +59%
IHAM
24
Integral Health Asset Management
New York
$3.83M +$890K +54,194 +33%
Charles Schwab
25
Charles Schwab
California
$3.67M -$97.2K -5,914 -3%

REPL Hedge Fund Activity: Q2 2022 in Review

102 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q2 2022, worth a combined $696M — up 4.7% from $665M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of REPL and 7 opened new positions — a net loss of 4 holders — while 40 trimmed existing stakes and 34 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $32.5M. The largest seller was Point72 Asset Management, cutting an estimated $11M.

  • 102 institutional investors held Replimune Group (REPL) as of Q2 2022, down from 107 in Q1 2022.
  • Funds reported $696M of Replimune Group stock for Q2 2022, up 4.7% quarter-over-quarter.
  • 7 funds opened new Replimune Group positions in Q2 2022 and 11 closed out, a net change of -4 holders.
  • The largest Replimune Group buyer in Q2 2022 was Baker Bros. Advisors, an estimated $32.5M added.
  • The largest Replimune Group seller in Q2 2022 was Point72 Asset Management, an estimated $11M sold.

Based on aggregated 13F filings for Q2 2022.